RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165 GBp and keeps an Outperform rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DIUXF:
- Diaceutics Director Increases Stake Signaling Confidence in Company Growth
- Diaceutics Enhances Employee Incentive Program with Share Awards
- Diaceutics Reports Strong FY 2024 Growth and Positive Outlook
- Diaceutics Opens New US Headquarters to Boost Market Presence
- Diaceutics Unveils Pathology Engagement Service with $1.8m Contract